Sleep apnea affects over 936 million adults globally, with many struggling to tolerate CPAP therapy. A three-year analysis of proximal hypoglossal nerve stimulation reveals sustained therapeutic benefits that could reshape treatment approaches for moderate-to-severe obstructive sleep apnea patients who cannot use traditional interventions effectively.
The THN3 trial tracked 104 participants with apnea-hypopnea indices between 20-65 events per hour and BMIs under 35 kg/m². Proximal nerve stimulation targeting the hypoglossal nerve maintained median AHI reductions of 15-18 events per hour at both 24 and 36 months, with effect sizes demonstrating 79% probability of superiority over baseline measurements. Oxygen desaturation improvements and quality-of-life gains remained stable throughout the observation period, matching one-year efficacy benchmarks.
This durability data fills a critical gap in sleep medicine's evidence base. Traditional CPAP therapy, while effective, suffers from poor long-term adherence rates approaching 50% discontinuation. Surgical alternatives like uvulopalatopharyngoplasty show variable outcomes and potential complications. The sustained three-year performance of proximal stimulation suggests the nervous system's adaptive response to electrical modulation remains stable over clinically relevant timeframes.
Particularly significant is the comparison framework against distal hypoglossal nerve stimulation from the STAR trial, providing head-to-head durability insights between different stimulation approaches. However, the 25% dropout rate warrants scrutiny, and the relatively homogeneous patient population limits generalizability to broader sleep apnea demographics. This technology represents an incremental but meaningful advance in neurostimulation therapeutics, offering hope for the substantial population unable to achieve consistent CPAP compliance.